
Metabolic medicine is changing faster than the evidence systems built to track it. New therapies for type 2 diabetes and obesity are reaching more patients, across more indications and through...

argenx already holds a minority stake in UNP and will acquire all remaining shares

The new site will expand research capabilities across immunology, neuroscience and oncology

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

The merger is not final and other companies will be able to bid for Karyopharm’s assets

Remibrutinib reduced relapse rates and improved disease progression rates

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?